Nirsevimab (Beyfortus) for RSV (2023)
The FDA approved nirsevimab, a long-acting monoclonal antibody given as a single dose to infants before RSV season. It was designed to prevent severe RSV in babies too young for vaccination or with weak vaccine response.
Nirsevimab became a standard preventive for infant RSV, complementing maternal vaccines.
It demonstrated that a single long-acting preventive biologic can succeed where vaccines have gaps.
AK0406 follows the same logic: a long-acting preventive for a respiratory virus, aimed at people vaccines protect poorly.
